{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-196961","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.052337+00:00","generated_at":"2026-05-31T10:48:19.469243+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zevra Therapeutics Reports Preliminary Q2 2024 Revenue of $4.2-$4.6 Million, Net Loss Widens to $18.9-$19.8 Million","bullets":["Revenue for Q2 2024 expected between $4.2M and $4.6M, down from $8.47M in Q2 2023 which included a $5.0M milestone payment from AZSTARYS license.","Net loss for Q2 2024 estimated at $18.9M to $19.8M, compared to a $2.6M net loss in the prior-year quarter.","Preliminary diluted net loss per share ranges from ($0.47) to ($0.45), versus ($0.08) in Q2 2023.","Cash and cash equivalents as of June 30, 2024 were approximately $49.3 million.","The decrease in revenue is partially offset by reimbursements under AZSTARYS License Agreement and increased French expanded access program reimbursements."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-196961","json":"https://secwatch.observer/filing/0001193125-24-196961.json","markdown":"https://secwatch.observer/filing/0001193125-24-196961.md","text":"https://secwatch.observer/filing/0001193125-24-196961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000119312524196961/0001193125-24-196961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000119312524196961/d881941d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:48:19.469243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}